| Budget Amount *help |
¥45,500,000 (Direct Cost: ¥35,000,000、Indirect Cost: ¥10,500,000)
Fiscal Year 2020: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2019: ¥9,360,000 (Direct Cost: ¥7,200,000、Indirect Cost: ¥2,160,000)
Fiscal Year 2018: ¥26,780,000 (Direct Cost: ¥20,600,000、Indirect Cost: ¥6,180,000)
|
|---|
| Outline of Final Research Achievements |
Considerable research efforts have been dedicated to the delivery of antibodies and other proteins having therapeutic potentials to cell interiors. However, there were certain rooms for improvement in the efficacy. Our laboratory developed a delivery peptide L17E capable of delivering antibodies into cells. In this study, we made structure-activity-relationship analyses of L17E to improve the efficacy. New delivery peptides were developed having ability of stimulating cellular uptake. Eventually, peptides having more than 10-fold delivery efficacy compared with L17E were developed. We found a potent macropinocytosis-inducing peptide SN21 and the analog P4A. Successful intracellular delivery of antibodies and other biomacromolecules was attained using the conjugates of these peptides with the LK15 membrane-lytic peptide.
|
